PCM
SGMO

Piermont Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Piermont Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-165,569
Closed -$505K – 271
2016
Q4 		$505K Sell
165,569
-3,510
-2% -$12.8K 0.12% 224
2016
Q3 		$783K Buy
169,079
+14,460
+9% +$73.5K 0.19% 188
2016
Q2 		$895K Buy
154,619
+74,050
+92% +$472K 0.23% 172
2016
Q1 		$487K Buy
+80,569
New +$484K 0.16% 147
2015
Q2 		– Sell
-48,430
Closed -$759K – 251
2015
Q1 		$759K Buy
48,430
+16,220
+50% +$251K 0.23% 108
2014
Q4 		$490K Buy
32,210
+8,040
+33% +$97.6K 0.17% 106
2014
Q3 		$261K Buy
+24,170
New +$316K 0.1% 181

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

Piermont Capital Management's SGMO Position: Q1 2017 in Review

Piermont Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2017, closing a stake of 165,569 shares — an estimated $505K sold.

Piermont Capital Management first reported a position in SGMO in Q3 2014 and held it in 7 quarters. The position peaked at $895K in Q2 2016. 118 funds tracked by Wall St. Rank hold SGMO as of Q1 2017.

  • Piermont Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2017 after selling out during the quarter.
  • Piermont Capital Management sold 165,569 SANGAMO THERAPEUTICS INC shares in Q1 2017, an estimated $505K.
  • Piermont Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 7 quarters.
  • Piermont Capital Management's SANGAMO THERAPEUTICS INC position peaked at $895K in Q2 2016.
  • 118 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2017.

Based on Piermont Capital Management's 13F filing for Q1 2017, filed 11 May 2017.